checkAd

    INVESTOR ALERT  712  0 Kommentare Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Nymox Pharmaceutical Corporation (NYMX) to Contact the Firm

    NEW YORK, NY--(Marketwired - November 26, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nymox Pharmaceutical Corporation ("Nymox" or the "Company") (NASDAQ: NYMX) of the January 26, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Nymox and the president and founder of the Company.

    A complaint has been filed in the United States District Court for the District of New Jersey on behalf of all persons who purchased or acquired Nymox common stock between January 31, 2011 and November 2, 2014 (the "Class Period").

    The complaint alleges that the Company and its executives violated federal securities laws with respect to its statements concerning its business, operations, and prospects.

    Specifically, the action alleges that during the Class Period, Nymox misrepresented and/or failed to disclose that trials of its most promising investigational drug, NX-1207, had revealed factors that indicated the drug's likely failure to achieve statistical significance.

    On November 2, 2014, the Company announced that the two Phase 3 studies had to be halted because the drug failed to meet primary efficacy endpoints.

    Following this news, the price of Nymox's stock declined by $4.21 per share, or over 81%, to close on November 3, 2014 at $0.93 per share.

    Request more information now by clicking here: www.faruqilaw.com/NYMX. There is no cost or obligation to you.

    Take Action

    If you invested in Nymox common stock or options between January 31, 2011 and November 2, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/NYMX. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Nymox's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

    Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

    Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

    FARUQI & FARUQI, LLP
    369 Lexington Avenue, 10th Floor
    New York, NY 10017
    Attn: Richard Gonnello, Esq.
    rgonnello@faruqilaw.com
    Telephone: (877) 247-4292 or (212) 983-9330





    Verfasst von Marketwired
    INVESTOR ALERT Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Nymox Pharmaceutical Corporation (NYMX) to Contact the Firm NEW YORK, NY--(Marketwired - November 26, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nymox Pharmaceutical Corporation ("Nymox" or the "Company") (NASDAQ: NYMX) of the January 26, 2015 deadline to seek …